Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III Study on the Safety, Pharmacokinetics, and Efficacy of Coagulation Factor VIIa (Recombinant) in Congenital Hemophilia A or B Pediatric Patients From Birth to <12 Years Old With Inhibitors to Factor VIII or IX: PerSept 2

Trial Profile

A Phase III Study on the Safety, Pharmacokinetics, and Efficacy of Coagulation Factor VIIa (Recombinant) in Congenital Hemophilia A or B Pediatric Patients From Birth to <12 Years Old With Inhibitors to Factor VIII or IX: PerSept 2

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 28 Feb 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Recombinant factor VIIa (Primary)
  • Indications Haemophilia A; Haemophilia B
  • Focus Registrational; Therapeutic Use
  • Acronyms PERSEPT2
  • Sponsors LFB Biotechnologies; rEVO Biologics
  • Most Recent Events

    • 14 Dec 2021 Results of subgroups analysis from (PERSEPT 1 and PERSEPT 2) assessing subset analysis suggests improved caregiver capacity to assess bleeding episode treatment success in three age subgroups, presented at the 63rd American Society of Hematology Annual Meeting and Exposition.
    • 01 Nov 2021 Results from three Phase 3 trials (PERSEPT 1, PERSEPT 2 and PERSEPT 3) assessing the EB safety, immunogenicity and thrombotic potential in children and adults who received EB for treatment of bleeding and perioperative care, published in the Haemophilia.
    • 01 Mar 2021 According to LFB media release, sBLA efficacy supplement is currently under FDA review, with a regulatory outcome expected by mid-2021
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top